Canna~Fangled Abstracts

Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis

By February 29, 2024No Comments

Review
. 2024 Feb 29.

doi: 10.1007/s40263-024-01072-5.

Online ahead of print.
Anastasiia D Shkodina 1, Mainak Bardhan 2, Hitesh Chopra 3, Onyekachi Emmanuel Anyagwa 4, Viktoriia A Pinchuk 1, Kateryna V Hryn 1, Anzhelina M Kryvchun 1, Dmytro I Boiko 5, Vinay Suresh 6, Amogh Verma 7, Mykhailo Yu Delva 1
Affiliations 

Abstract

Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte’s phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects. The literature search was conducted across two databases, PubMed, and Google Scholar. Eligible studies included clinical trials, observational studies, meta-analyses, systematic reviews, and narrative reviews. The objective of this article is to provide an overview of literature on pharmacological and non-pharmacological strategies employed in the management of neuropathic pain in multiple sclerosis. Pharmacological options include cannabinoids, muscle relaxants (tizanidine, baclofen, dantrolene), anticonvulsants (benzodiazepines, gabapentin, phenytoin, carbamazepine, lamotrigine), antidepressants (duloxetine, venlafaxine, tricyclic antidepressants), opioids (naltrexone), and botulinum toxin variants, which have evidence from various clinical trials. Non-pharmacological approaches for trigeminal neuralgia may include neurosurgical methods. Non-invasive methods, physical therapy, and psychotherapy (cognitive behavioral therapy, acceptance and commitment therapy and mindfulness-based stress reduction) may be recommended for patients with neuropathic pain in multiple sclerosis. The choice of treatment depends on the severity and type of pain as well as other factors, such as patient preferences and comorbidities. There is a pressing need for healthcare professionals and researchers to prioritize the development of better strategies for managing multiple sclerosis-induced neuropathic pain.

PubMed Disclaimer

References

    1. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172:3–13. https://doi.org/10.1016/j.neurol.2015.10.006 . – DOI – PubMed
    1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler J. 2020;26:1816–21. https://doi.org/10.1177/1352458520970841 . – DOI
    1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–4. https://doi.org/10.1212/WNL.0000000000000768 . – DOI – PubMed – PMC
    1. Chisari CG, Sgarlata E, Arena S, D’Amico E, Toscano S, Patti F. An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opin Pharmacother. 2020;21:2249–63. https://doi.org/10.1080/14656566.2020.1757649 . – DOI – PubMed
    1. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch-Henriksen N, Bach FW. Pain in patients with multiple sclerosis. Arch Neurol. 2003;60:1089. https://doi.org/10.1001/archneur.60.8.1089 . – DOI – PubMed

Publication types

Leave a Reply